Edesa Biotech Inc Share Price Today: Live Updates & Key Insights

Edesa Biotech Inc share price today is $7.14, up 1.66%. The stock opened at $7.46 against the previous close of $7.23, with an intraday high of $9.31 and low of $6.6792.

Edesa Biotech Inc Share Price Chart

Edesa Biotech Inc

us-stock
To Invest in {{usstockname}}
us-stock

Edesa Biotech Inc Share Price Performance

$7.14 0.0166(1.66%) EDSA at 23 Mar 2026 12:49 PM Biotechnology
Lowest Today 6.6792
Highest Today 9.31
Today’s Open 7.46
Prev. Close 7.23
52 Week High 9.37
52 Week Low 0.72
Day’s Range: Low 6.6792 High 9.31
52-Week Range: Low 0.72 High 9.37
1 day return -
1 Week return +42.49
1 month return +715.84
3 month return +400.68
6 month return +195.95
1 year return +215.08
3 year return -0.54
5 year return -80.94
10 year return -

Edesa Biotech Inc Institutional Holdings

Rubric Capital Management LP 8.24

Stonepine Capital Management Llc 8.24

Velan Capital Investment Management LP 8.24

Nantahala Capital Management, LLC 7.49

Citadel Advisors Llc 0.64

Geode Capital Management, LLC 0.56

Vanguard Group Inc 0.45

Vanguard Institutional Extnd Mkt Idx Tr 0.44

Fidelity Extended Market Index 0.38

Persistent Asset Partners Limited 0.15

Fidelity Series Total Market Index 0.06

Spartan Extended Market Index Pool F 0.06

Spartan Total Market Index Pool G 0.03

Tower Research Capital LLC 0.03

Citigroup Inc 0.02

Northern Trust Extended Eq Market Idx 0.02

NT Ext Equity Mkt Idx Fd - L 0.02

Royal Bank of Canada 0.02

UBS Group AG 0.02

Fidelity Nasdaq Composite Index 0.02

NT Ext Equity Mkt Idx Fd - NL 0.01

Fidelity Total Market Index 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

State St US Extended Mkt Indx NL Cl C 0.01

SSgA U.S. Total Market Index Strategy 0.00

State St US Ttl Mkt Indx NL Cl A 0.00

Vanguard U.S. Eq Idx £ Acc 0.00

TD Waterhouse Canada Inc 0.00

Fifth Third Bancorp 0.00

Global Retirement Partners, LLC. 0.00

Bank of America Corp 0.00

Northern Trust Wilshire 5000 0.00

NT US Market Cap Idx Fd - L 0.00

Barclays PLC 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

Banque Cantonale Vaudoise 0.00

Danske Bank A/S. 0.00

Dogwood Wealth Management LLC 0.00

Edesa Biotech Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Edesa Biotech Inc Fundamentals

Market Cap 61.36 M

PB Ratio 12.9614

PE Ratio 0.0

Enterprise Value 59.34 M

Total Assets 13.53 M

Volume 2473001

Edesa Biotech Inc Company Financials

Annual Revenue FY25:0 0.0M, FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M

Annual Profit FY25:-119273 -0.1M, FY24:null 0.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:0 0.0M

Annual Net worth FY25:-7185523 -7.2M, FY24:-6170045 -6.2M, FY23:-8374415 -8.4M, FY22:-17548924 -17.5M, FY21:-13343150 -13.3M

Quarterly Revenue Q4/2025:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:0 0.0M

Quarterly Profit Q4/2025:-25459 -0.0M, Q3/2025:-25868 -0.0M, Q2/2025:-25787 -0.0M, Q1/2025:-24509 -0.0M, Q4/2024:null 0.0M

Quarterly Net worth Q4/2025:-2247669 -2.2M, Q3/2025:-2228358 -2.2M, Q2/2025:-1749464 -1.7M, Q1/2025:-1590448 -1.6M, Q4/2024:-1617253 -1.6M

About Edesa Biotech Inc & investment objective

Company Information Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Dr. Pardeep Nijhawan FRCPC, M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Edesa Biotech Inc FAQs

What is the share price of Edesa Biotech Inc today?

The current share price of Edesa Biotech Inc is $7.14.

Can I buy Edesa Biotech Inc shares in India?

Yes, Indian investors can buy Edesa Biotech Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Edesa Biotech Inc shares in India?

You can easily invest in Edesa Biotech Inc shares from India by:

Can I buy fractional shares of Edesa Biotech Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Edesa Biotech Inc?

Edesa Biotech Inc has a market cap of $61.36 M.

In which sector does Edesa Biotech Inc belong?

Edesa Biotech Inc operates in the Biotechnology sector.

What documents are required to invest in Edesa Biotech Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Edesa Biotech Inc?

The PE ratio of Edesa Biotech Inc is N/A and the PB ratio is 12.96.